Truist Securities adjusted its price target for American Healthcare REIT (NYSE: AHR) downward slightly, while affirming a Buy rating. The move comes as the firm reassesses its outlook for the broader REIT sector heading into 2026.
Analyst coverage initiated with an 'Overweight' rating and a $413 price target points to a transformed contractor poised to capitalize on data center demand, grid modernization, and reshoring trends.
Analyst firm Argus has raised its price target for Sanmina Corporation (SANM) to $200, maintaining a Buy rating following the company's better-than-expected Q1 2026 results and robust positioning in key growth markets.
InterDigital (NASDAQ: IDCC) has laid out an ambitious financial roadmap for fiscal year 2026, forecasting revenues up to $775 million. The outlook is supported by a newly inked licensing agreement with LG Electronics and a key smartphone renewal, signaling strong momentum in its patent portfolio.
Citigroup reaffirms its bullish stance on AppLovin (APP), highlighting the rapid adoption of its Axon platform by e-commerce clients and improved customer quality as key growth drivers, with a price target of $820.
Investment firms Stifel and Northland have raised their price targets on Ondas Holdings (ONDS), following a virtual investor day where management outlined an ambitious growth roadmap, highlighting the company's unique position in military drones and private wireless networks.
Analyst Quinn Bolton of Needham maintains a Buy rating on D-Wave Quantum (QBTS), highlighting the company's strengthened competitive position after its acquisition of Quantum Circuits, which creates the world's only dual-platform quantum computing firm.
B. Riley analyst Craig Ellis has upgraded Rigetti Computing (NASDAQ: RGTI) from 'Neutral' to 'Buy', maintaining a $35 price target. The upgrade follows the company's announcement of an $8.4 million order to supply a 108-qubit quantum computer to India's premier R&D agency, C-DAC, providing clearer visibility into its 2026 commercial trajectory.
Fueled by explosive growth in AI infrastructure spending, Nvidia's commanding market position sets the stage for significant potential gains. Analysts project a revenue path that could see its stock reach new heights by the end of the decade.
Oracle shares face continued pressure over debt and AI infrastructure costs, but Guggenheim's bullish $400 price target suggests potential for a multi-year rebound if execution risks are managed.
As demand surges post-pandemic, Royal Caribbean Group is committing billions to new ships and destinations. CFO Naftali Holtz details the balancing act between ambitious growth, shareholder returns, and leveraging AI to enhance the passenger experience.
Box, Inc. strengthens its enterprise cloud offerings with the general release of Box Extract, an AI-driven data intelligence tool. The launch coincides with bullish analyst sentiment, including a Citi price target suggesting significant upside.
As a temporary halt in Russian airstrikes on Kyiv brokered by former U.S. President Trump nears its end, Ukraine is urgently working to strengthen its air defenses. Analysts caution the lull may be a tactical move by Moscow to bolster its diplomatic leverage rather than a step toward peace.
Bitcoin's sharp decline continues, breaching key support levels as experts warn of a potential slide toward $70,000. Market uncertainty fueled by Trump's controversial Fed chair nomination triggers a broader crypto sell-off.
The U.S. Office of the Comptroller of the Currency has granted Nubank conditional approval to establish a national bank, a significant step that could see the digital banking leader offer federally regulated crypto custody alongside traditional banking products in the United States.
Despite recent downgrades from two major Wall Street firms, analysts maintain that Nutanix (NTNX) shares hold substantial upside potential, even as questions emerge about the pace of its near-term growth.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Once hailed as twin hedges against fiat currency, silver and Bitcoin are now charting starkly different courses. Driven by a tangible industrial shortage, silver's historic rally contrasts with Bitcoin's slump, which is increasingly tethered to broader financial liquidity and risk sentiment.
A sharp sell-off grips both digital and traditional safe havens, with Bitcoin nearing a critical $80,000 level and gold suffering its worst drop in months, fueled by Fed uncertainty and tech sector anxieties.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
